Advice

following an abbreviated submission:

doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.

Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) offers an additional treatment choice of NNRTI-based single-tablet regimen for this indication.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

 

Download detailed advice732KB (PDF)

Download

Medicine details

Medicine name:
doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo)
SMC ID:
SMC2333
Indication:

For the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.

Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Infections
Submission type
Abbreviated
Status
Accepted
Date advice published
08 March 2021